Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Kalaris Therapeutics, Inc. (KLRS)
Company Research
Source: GlobeNewswire
PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November 13, 2025Time: 3:20 – 3:50pm ETLocation: Lotte New York Palace Hotel, New York, NY Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. About Kalaris Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist
Show less
Read more
Impact Snapshot
Event Time:
KLRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KLRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KLRS alerts
High impacting Kalaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KLRS
News
- Kalaris Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire
- Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.MarketBeat
- Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial OfficerGlobeNewswire
- Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.MarketBeat
- Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=KLRS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
KLRS
Earnings
- 5/14/25 - Miss
KLRS
Analyst Actions
- 11/3/25 - Citigroup Inc.